커드리널 테라퓨틱스CVKD 주가

♻️ 재탕[4] 내부자 거래

[4] 내부자 거래

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 2

[144] 144

CVKD: Designing Phase 3 Trial for CAD-1005 in HIT

By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Planning for Phase 3 Registration Trial of CAD-1005 in HIT On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an ‘End-of-Phase 2’ meeting with the U.S. Food and Drug Administration (FDA) in which the agency provided critical guidance on the company’s upcoming Phase 3 pivotal trial for CAD-1005

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT)PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting

Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate

Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses of $(2.09) per share

[8-K] 중대 사건 — CURRENT REPORT

[10-Q] 분기 실적 — QUARTERLY REPORT

[8-K] 중대 사건 — CURRENT REPORT